Thomas Spires

1.3k total citations · 1 hit paper
15 papers, 790 citations indexed

About

Thomas Spires is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Thomas Spires has authored 15 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Thomas Spires's work include Cancer Immunotherapy and Biomarkers (5 papers), Estrogen and related hormone effects (4 papers) and Prostate Cancer Treatment and Research (4 papers). Thomas Spires is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Estrogen and related hormone effects (4 papers) and Prostate Cancer Treatment and Research (4 papers). Thomas Spires collaborates with scholars based in United States, France and Australia. Thomas Spires's co-authors include Marco M. Gottardis, Ricardo M. Attar, Cheryl A. Rizzo, J. Suso Platero, Michael Quigley, Liang Schweizer, Mary Ellen Cvijic, Qiuyan Wu, Tai-An Lin and Canan Kasikara and has published in prestigious journals such as Journal of the American College of Cardiology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Thomas Spires

15 papers receiving 782 citations

Hit Papers

First-line nivolumab plus ipilimumab versus chemotherapy ... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    2022 158 citations Solange Peters, Arnaud Scherpereel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Spires United States 12 268 223 182 170 132 15 790
Elena V. Efimova United States 20 101 0.4× 207 0.9× 378 2.1× 576 3.4× 146 1.1× 53 1.1k
Suliman Al‐Fayoumi United States 13 121 0.5× 91 0.4× 131 0.7× 415 2.4× 374 2.8× 23 1.2k
Yuko Sugiyama Japan 14 127 0.5× 70 0.3× 346 1.9× 244 1.4× 97 0.7× 62 968
Paweł Uruski Poland 17 86 0.3× 127 0.6× 225 1.2× 316 1.9× 46 0.3× 52 841
Yingying Hao China 18 103 0.4× 242 1.1× 174 1.0× 504 3.0× 34 0.3× 48 874
Jiasheng Zheng China 20 192 0.7× 124 0.6× 269 1.5× 321 1.9× 36 0.3× 54 1.0k
Raimondo Di Liello Italy 13 228 0.9× 87 0.4× 357 2.0× 265 1.6× 18 0.1× 33 738
Aijun Liu China 14 507 1.9× 32 0.1× 125 0.7× 334 2.0× 89 0.7× 66 956
Nathan D. Seligson United States 13 165 0.6× 40 0.2× 213 1.2× 192 1.1× 24 0.2× 38 532

Countries citing papers authored by Thomas Spires

Since Specialization
Citations

This map shows the geographic impact of Thomas Spires's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Spires with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Spires more than expected).

Fields of papers citing papers by Thomas Spires

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Spires. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Spires. The network helps show where Thomas Spires may publish in the future.

Co-authorship network of co-authors of Thomas Spires

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Spires. A scholar is included among the top collaborators of Thomas Spires based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Spires. Thomas Spires is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Zalcman, Gérard, Robin Cornelissen, Laurent Greillier, et al.. (2022). LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Annals of Oncology. 33. S1438–S1439. 5 indexed citations
3.
Velaparthi, Upender, Mark G. Saulnier, David B. Frennesson, et al.. (2022). The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. Bioorganic & Medicinal Chemistry Letters. 75. 128951–128951. 7 indexed citations
4.
Peters, Solange, Arnaud Scherpereel, Robin Cornelissen, et al.. (2022). First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 33(5). 488–499. 158 indexed citations breakdown →
5.
6.
Davra, Viralkumar, Sushil Kumar, Ke Geng, et al.. (2020). Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Cancer Research. 81(3). 698–712. 61 indexed citations
7.
Chirinos, Julio A., Alena Orlenko, Lei Zhao, et al.. (2020). Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 75(11). 1281–1295. 153 indexed citations
8.
Caetano, Mauricio S., Ahmed Younes, Hampartsoum B. Barsoumian, et al.. (2019). Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clinical Cancer Research. 25(24). 7576–7584. 54 indexed citations
9.
Prenner, Stuart B., Anupam Kumar, Lei Zhao, et al.. (2019). Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). The American Journal of Cardiology. 125(4). 575–582. 30 indexed citations
10.
Kasikara, Canan, Viralkumar Davra, David Calianese, et al.. (2019). Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti–PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer. Cancer Research. 79(10). 2669–2683. 93 indexed citations
11.
Shan, Weifang, Aaron Balog, Xiao Zhu, et al.. (2016). [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 26(23). 5707–5711. 11 indexed citations
12.
Attar, Ricardo M., Maria Jure–Kunkel, Aaron Balog, et al.. (2009). Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer. Cancer Research. 69(16). 6522–6530. 38 indexed citations
13.
Schweizer, Liang, Cheryl A. Rizzo, Thomas Spires, et al.. (2008). The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biology. 9(1). 4–4. 98 indexed citations
14.
Fink, Brian E., Ashvinikumar V. Gavai, John S. Tokarski, et al.. (2006). Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorganic & Medicinal Chemistry Letters. 16(6). 1532–1536. 36 indexed citations
15.
Spires, Thomas, Brian E. Fink, Ellen K. Kick, et al.. (2005). Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3). The Prostate. 65(2). 159–170. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena V. Efimova Breakdown of academic impact, for papers by Suliman Al‐Fayoumi Breakdown of academic impact, for papers by Yuko Sugiyama Breakdown of academic impact, for papers by Paweł Uruski Breakdown of academic impact, for papers by Yingying Hao Breakdown of academic impact, for papers by Jiasheng Zheng Breakdown of academic impact, for papers by Raimondo Di Liello Breakdown of academic impact, for papers by Aijun Liu Breakdown of academic impact, for papers by Nathan D. Seligson
Rankless by CCL
2026